INDP Indaptus Therapeutics, Inc.

Nasdaq indaptusrx.com


$ 3.63 $ -0.02 (-0.55 %)    

Friday, 24-Oct-2025 15:38:48 EDT
QQQ $ 617.07 $ 1.07 (0.17 %)
DIA $ 472.17 $ 2.30 (0.49 %)
SPY $ 677.12 $ 0.65 (0.09 %)
TLT $ 91.46 $ -0.10 (-0.11 %)
GLD $ 377.47 $ -1.10 (-0.29 %)
$ 3.55
$ 3.65
$ 3.59 x 7
$ 3.67 x 100
$ 3.56 - $ 3.63
$ 2.22 - $ 47.60
25,554
na
3.93M
$ 1.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of t...

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 indaptus-reports-partial-response-from-decoy20-monotherapy-in-urothelial-cancer-combo-with-pd-1-inhibitor-shows-favorable-safety

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastasesDecoy20 combination with PD-...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION